Off-target binding is a significant hurdle in the development of antibody-based therapies, contributing to both drug attrition and adverse events in patients. Recent analysis from our own work identified a surprisingly high off-target rate across the industry, with up to one third of antibody drugs displaying off-target binding. In this presentation, we will discuss the emergence of cell-based protein arrays, including the Membrane Proteome Array, as an alternative and improved technology to assess antibody specificity.

Integral Molecular is the industry leader in isolating and characterizing monoclonal antibodies (MAbs) against the most challenging membrane protein targets including GPCRs, ion channels, transporters, and viral proteins. 

Integral Molecular offers:

• Membrane Proteome Array™: Antibody specificity screening for lead selection and IND safety profilingusing ISO 9001 certified processes. 

• Lipoparticles: Virus-like particles with high concentrations of native membrane proteins for optimized immunization and screening.

• Epitope Mapping: Conformational, high-resolution epitope mapping that informs mechanism of action and strengthens intellectual property.

• VerSaMAb Antibody Reagents: Extensively Validated, Recombinant and Specific antibodies for applications including flow cytometry and immunofluorescence.

• MPS Antibody Discovery platform: Our platform delivers lead candidate MAbs through IND. Leveraging advanced antigens (Lipoparticles, mRNA), divergent host species and phage display, we achieve unprecedented success in discovering antibodies against complex and conserved targets.